Actively Recruiting
Evaluating the Effects and Safety of TRIV-573 Injections in Adults with Moderate to Severe Atopic Dermatitis
Led by Triveni Bio · Updated on 2026-10-28
90
Participants Needed
17
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug TRIV-573 for treating moderate to severe atopic dermatitis in adults. This phase 2, randomized, double-blind, placebo-controlled study aims to assess both the effectiveness and safety of multiple doses of TRIV-573 compared to placebo. The study is sponsored by Triveni Bio and focuses on improving symptoms of atopic dermatitis over 16 weeks. Participants will be randomly assigned to receive five subcutaneous injections of either TRIV-573 or a placebo. The study includes a screening period lasting up to 30 days before treatment begins. The total duration for each participant is up to 40 weeks, covering treatment and follow-up phases. During the study, participants will undergo regular assessments to monitor their skin condition and safety. Researchers will measure the percentage of participants showing improvement in atopic dermatitis from baseline through week 16. Safety will be evaluated by tracking adverse events and analyzing blood samples for drug levels and antibody formation through week 36. Participants will attend scheduled visits for these evaluations throughout the study period.
CONDITIONS
Brief Title
A Study Evaluating TRIV-573 in Atopic Dermatitis
Research Team
T
Triveni Bio, Inc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here